Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Multivariate analyses showed that NAT1 and TWIST1 staining was significantly associated with EMT status regardless of the estrogen receptor status of the tumors (p values: 0.020 and 0.027, respectively).
|
30610490 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
NAT1 expression showed a trimodal distribution in breast cancer samples (n = 1980) but not in tumor tissue from ovarian, prostate, cervical or colorectal cancers.
|
29969986 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The expression levels of the up-regulated genes (NAT1, BBS1 and PH-4) were also found to be correlated to epithelial to mesenchymal transition status of the tumour.
|
26965286 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of expression of NAT1 were positively correlated with those of ERα (P < 0.0001) and PgR (P < 0.0001), but negatively correlated with both tumor grade and size (P < 0.0001).
|
25528056 |
2014 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression rate of NAT1 mRNA was lower in the tumors from the resistant group than in control tumors (28.6% vs. 65.2%, p = 0.031).
|
20628863 |
2010 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.
|
17973251 |
2008 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Relapse-free survival was longer among patients with FMO5-overexpressing tumors or NAT1-overexpressing tumors (P = 0.0066 and P = 0.000052, respectively), but only NAT1 status retained prognostic significance in Cox multivariate regression analysis (P = 0.0013).
|
15084249 |
2004 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
NAT-1 overexpression in clinical breast cancers was confirmed at the mRNA level and immunohistochemical analysis of NAT-1 in 108 breast cancer donors demonstrated a strong association of NAT-1 staining with estrogen receptor-positive tumors.
|
14517345 |
2003 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Interestingly, the risk observed for NAT1*10 appears to be solely associated with advanced-stage tumors (OR = 4.8, P < 0.001), suggesting a possible role in progression to advanced disease.
|
10918189 |
2000 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
When the combined risk of NAT1*10 allele from smoking and tumor differentiation was calculated, we found that the risk of the NAT1*10 allele with heavy smoking was increased among the well - differentiated type of gastric adenocarcinoma (OR = 4.24, 95% CI 0.87-20.6).
|
10585581 |
2000 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this study, fluorescence in situ hybridization (FISH) was used for study of the relationship between chromosome 8 deletions in the region of NAT1 and NAT2 and grade and stage of tumor in bladder cancer.
|
10398432 |
1999 |
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In mutation 1 group, the NAT1 allele 10 was a risk factor for distal tumor location, both alone (P = 0.028) and combined with the GSTT1-positive genotype (P = 0.008).
|
9834266 |
1998 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Southern blot analysis of 66 esophageal adenocarcinomas demonstrated only CTSB and FDFT1 were consistently amplified in eight (12.1%) of the tumors.Neither NAT-1 nor LPL were amplified.
|
9770500 |
1998 |